Luye Pharma Group (HK:2186) has released an update.
Luye Pharma Group Ltd. has announced a significant deal where an investor will inject up to RMB 1,600 million into Shenzhen Luye, resulting in the investor acquiring a 34.8% equity stake. This investment, structured in several stages, begins with a RMB 1,000 million purchase of a 25% interest in Nanjing Luye. The transaction is classified as a discloseable transaction under Hong Kong Listing Rules, modifying the Group’s holding in Shenzhen Luye and avoiding the need for shareholder approval.
For further insights into HK:2186 stock, check out TipRanks’ Stock Analysis page.
